Effect of price increase of adrenocorticotropic hormone on treatment practices of infantile spasms

Carter Wray, Timothy A. Benke

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Intramuscular adrenocorticotropic hormone putatively constitutes the most efficacious treatment for infantile spasms. Adrenocorticotropic hormone in the United States is an "orphan drug," made by a single manufacturer. The price of adrenocorticotropic hormone increased almost 14-fold on August 27, 2007. We sought to evaluate the impact of this price increase on treatment practices at our institution, using a retrospective chart review of all children with infantile spasms treated during 2007-2009. We identified 97 patients whose spasms were treated using antiepileptic drugs, and we determined the length of stay for those hospitalized to initiate adrenocorticotropic hormone. Patients before the price increase were more likely to have been treated with adrenocorticotropic hormone as first medication, and were hospitalized 2.2 ± 0.5 S.D. days for initiation. Patients after the price increase were more likely to have been treated initially with oral antiepileptic drugs rather than adrenocorticotropic hormone (P <0.002). Those commencing adrenocorticotropic hormone after the price increase were hospitalized significantly longer (5.1 ± 0.6 days S.D., P <0.001). Treatment choices need to be evidence-based, but other factors often influence them.

Original languageEnglish (US)
Pages (from-to)163-166
Number of pages4
JournalPediatric Neurology
Volume43
Issue number3
DOIs
StatePublished - Sep 2010
Externally publishedYes

Fingerprint

Infantile Spasms
Adrenocorticotropic Hormone
Anticonvulsants
Therapeutics
Orphan Drug Production
Spasm
Length of Stay

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Developmental Neuroscience
  • Neurology

Cite this

Effect of price increase of adrenocorticotropic hormone on treatment practices of infantile spasms. / Wray, Carter; Benke, Timothy A.

In: Pediatric Neurology, Vol. 43, No. 3, 09.2010, p. 163-166.

Research output: Contribution to journalArticle

@article{dbf75bcc447b47a38cb338dee33a6f91,
title = "Effect of price increase of adrenocorticotropic hormone on treatment practices of infantile spasms",
abstract = "Intramuscular adrenocorticotropic hormone putatively constitutes the most efficacious treatment for infantile spasms. Adrenocorticotropic hormone in the United States is an {"}orphan drug,{"} made by a single manufacturer. The price of adrenocorticotropic hormone increased almost 14-fold on August 27, 2007. We sought to evaluate the impact of this price increase on treatment practices at our institution, using a retrospective chart review of all children with infantile spasms treated during 2007-2009. We identified 97 patients whose spasms were treated using antiepileptic drugs, and we determined the length of stay for those hospitalized to initiate adrenocorticotropic hormone. Patients before the price increase were more likely to have been treated with adrenocorticotropic hormone as first medication, and were hospitalized 2.2 ± 0.5 S.D. days for initiation. Patients after the price increase were more likely to have been treated initially with oral antiepileptic drugs rather than adrenocorticotropic hormone (P <0.002). Those commencing adrenocorticotropic hormone after the price increase were hospitalized significantly longer (5.1 ± 0.6 days S.D., P <0.001). Treatment choices need to be evidence-based, but other factors often influence them.",
author = "Carter Wray and Benke, {Timothy A.}",
year = "2010",
month = "9",
doi = "10.1016/j.pediatrneurol.2010.04.005",
language = "English (US)",
volume = "43",
pages = "163--166",
journal = "Pediatric Neurology",
issn = "0887-8994",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Effect of price increase of adrenocorticotropic hormone on treatment practices of infantile spasms

AU - Wray, Carter

AU - Benke, Timothy A.

PY - 2010/9

Y1 - 2010/9

N2 - Intramuscular adrenocorticotropic hormone putatively constitutes the most efficacious treatment for infantile spasms. Adrenocorticotropic hormone in the United States is an "orphan drug," made by a single manufacturer. The price of adrenocorticotropic hormone increased almost 14-fold on August 27, 2007. We sought to evaluate the impact of this price increase on treatment practices at our institution, using a retrospective chart review of all children with infantile spasms treated during 2007-2009. We identified 97 patients whose spasms were treated using antiepileptic drugs, and we determined the length of stay for those hospitalized to initiate adrenocorticotropic hormone. Patients before the price increase were more likely to have been treated with adrenocorticotropic hormone as first medication, and were hospitalized 2.2 ± 0.5 S.D. days for initiation. Patients after the price increase were more likely to have been treated initially with oral antiepileptic drugs rather than adrenocorticotropic hormone (P <0.002). Those commencing adrenocorticotropic hormone after the price increase were hospitalized significantly longer (5.1 ± 0.6 days S.D., P <0.001). Treatment choices need to be evidence-based, but other factors often influence them.

AB - Intramuscular adrenocorticotropic hormone putatively constitutes the most efficacious treatment for infantile spasms. Adrenocorticotropic hormone in the United States is an "orphan drug," made by a single manufacturer. The price of adrenocorticotropic hormone increased almost 14-fold on August 27, 2007. We sought to evaluate the impact of this price increase on treatment practices at our institution, using a retrospective chart review of all children with infantile spasms treated during 2007-2009. We identified 97 patients whose spasms were treated using antiepileptic drugs, and we determined the length of stay for those hospitalized to initiate adrenocorticotropic hormone. Patients before the price increase were more likely to have been treated with adrenocorticotropic hormone as first medication, and were hospitalized 2.2 ± 0.5 S.D. days for initiation. Patients after the price increase were more likely to have been treated initially with oral antiepileptic drugs rather than adrenocorticotropic hormone (P <0.002). Those commencing adrenocorticotropic hormone after the price increase were hospitalized significantly longer (5.1 ± 0.6 days S.D., P <0.001). Treatment choices need to be evidence-based, but other factors often influence them.

UR - http://www.scopus.com/inward/record.url?scp=77955526547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955526547&partnerID=8YFLogxK

U2 - 10.1016/j.pediatrneurol.2010.04.005

DO - 10.1016/j.pediatrneurol.2010.04.005

M3 - Article

C2 - 20691936

AN - SCOPUS:77955526547

VL - 43

SP - 163

EP - 166

JO - Pediatric Neurology

JF - Pediatric Neurology

SN - 0887-8994

IS - 3

ER -